Compare KRSA & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRSA | TSLX |
|---|---|---|
| Founded | 2024 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2019 | 2011 |
| Metric | KRSA | TSLX |
|---|---|---|
| Price | $30.08 | $17.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $44.00 | $19.77 |
| AVG Volume (30 Days) | 144.5K | ★ 522.8K |
| Earning Date | 11-16-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 9.94% |
| EPS Growth | ★ 8.26 | N/A |
| EPS | N/A | ★ 0.51 |
| Revenue | ★ $2,074,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.55 |
| P/E Ratio | ★ N/A | $34.92 |
| Revenue Growth | ★ 3.70 | N/A |
| 52 Week Low | $29.03 | $16.04 |
| 52 Week High | $37.27 | $22.84 |
| Indicator | KRSA | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.62 | 54.36 |
| Support Level | $29.67 | $17.14 |
| Resistance Level | $35.78 | $17.94 |
| Average True Range (ATR) | 2.32 | 0.40 |
| MACD | -0.00 | 0.13 |
| Stochastic Oscillator | 23.33 | 66.38 |
Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.